Provided is a solid catalyst component for olefin polymerization comprising an electron-donating compound other than a phthalate, the solid catalyst component being equal in the olefin-polymerizing activity and in the primary physical properties of the resulting polymer such as stereoregularity and molecular weight distribution to those with use of a phthalate as an electron-donating compound. A solid catalyst component for olefin polymerization comprises a magnesium atom, a titanium atom, a halogen atom, an ester compound (A) represented by a general formula (1) and a diester compound (B) represented by a general formula (2), wherein a ratio represented by the following expression:
(content (mass %) of ester compound (A)/content (mass %) of diester compound (B))
is 0.05 to 50.

Provided is a solid catalyst component for olefin polymerization comprising an electron-donating compound other than a phthalate, the solid catalyst component being equal in the olefin-polymerizing activity and in the primary physical properties of the resulting polymer such as stereoregularity and molecular weight distribution to those with use of a phthalate as an electron-donating compound. A solid catalyst component for olefin polymerization comprises a magnesium atom, a titanium atom, a halogen atom, an ester compound (A) represented by a general formula (1) and a diester compound (B) represented by a general formula (2), wherein a ratio represented by the following expression:
(content (mass %) of ester compound (A)/content (mass %) of diester compound (B))
is 0.05 to 50.

Compositions include ether ester compounds derived from neo-acids, lubricating oil base stocks containing such ester compounds, and lubricating oil compositions containing such ester compounds. Methods can include making and formulating compositions containing ether ester compounds derived from neo-acids.

Compositions include ether ester compounds derived from neo-acids, lubricating oil base stocks containing such ester compounds, and lubricating oil compositions containing such ester compounds. Methods can include making and formulating compositions containing ether ester compounds derived from neo-acids.

The present invention provides modified cycloalkyne compounds; and method of use of such compounds in modifying biomolecules. The present invention features a cycloaddition reaction that can be carried out under physiological conditions. In general, the invention involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provide for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).

The present invention provides modified cycloalkyne compounds; and method of use of such compounds in modifying biomolecules. The present invention features a cycloaddition reaction that can be carried out under physiological conditions. In general, the invention involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provide for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).

There is provided a novel optically active bisphosphinomethane useful as a ligand for an asymmetric catalyst, excellent in oxidation resistance in air, and easy in handling. There is also provided a transition metal complex using the optically active bisphosphinoraethane having excellent asymmetric catalytic ability as a ligand. The optically active bisphosphinomethane is represented by the general formula (1), and the transition metal complex has the optically active bisphosphinomethane as a ligand.

##STR00001##

(In the formula, R.sup.1 represents an adamantyl group; R.sup.2 represents a branched alkyl group having 3 or more carbon atoms; and * represents an asymmetric center on a phosphorus atom.)

There is provided a novel optically active bisphosphinomethane useful as a ligand for an asymmetric catalyst, excellent in oxidation resistance in air, and easy in handling. There is also provided a transition metal complex using the optically active bisphosphinoraethane having excellent asymmetric catalytic ability as a ligand. The optically active bisphosphinomethane is represented by the general formula (1), and the transition metal complex has the optically active bisphosphinomethane as a ligand.

##STR00001##

(In the formula, R.sup.1 represents an adamantyl group; R.sup.2 represents a branched alkyl group having 3 or more carbon atoms; and * represents an asymmetric center on a phosphorus atom.)

A resveratrol derivative of the compound of formula I or a pharmaceutically acceptable salt thereof are effective for treating a fibrotic disease.

##STR00001##

In formula I, R.sub.1 is hydrogen or C.sub.1-C.sub.4 alkyl, R.sub.2 and R.sub.3 are each independently C.sub.1-C.sub.3 alkyl or C.sub.1-C.sub.3 deuterated alkyl, and R.sub.2 and R.sub.3 are the same or different; the C.sub.1-C.sub.4 alkyl or C.sub.1-C.sub.3 alkyl is optionally substituted with one or more substituents each independently selected from the group consisting of halogen (for example, fluorine, chlorine, bromine, iodine), methyl, hydroxyl, ethyl, amino, methoxy, and nitro; and R.sub.4 and R.sub.5 are substituted or unsubstituted C.sub.1-C.sub.3 alkyl. The fibrotic disease is selected from the group consisting of liver fibrosis, lung fibrosis, kidney fibrosis, and cardiac fibrosis.

A resveratrol derivative of the compound of formula I or a pharmaceutically acceptable salt thereof are effective for treating a fibrotic disease.

##STR00001##

In formula I, R.sub.1 is hydrogen or C.sub.1-C.sub.4 alkyl, R.sub.2 and R.sub.3 are each independently C.sub.1-C.sub.3 alkyl or C.sub.1-C.sub.3 deuterated alkyl, and R.sub.2 and R.sub.3 are the same or different; the C.sub.1-C.sub.4 alkyl or C.sub.1-C.sub.3 alkyl is optionally substituted with one or more substituents each independently selected from the group consisting of halogen (for example, fluorine, chlorine, bromine, iodine), methyl, hydroxyl, ethyl, amino, methoxy, and nitro; and R.sub.4 and R.sub.5 are substituted or unsubstituted C.sub.1-C.sub.3 alkyl. The fibrotic disease is selected from the group consisting of liver fibrosis, lung fibrosis, kidney fibrosis, and cardiac fibrosis.